US Patent 8785398 Methods of treatment using CTLA4 mutant molecules

Patent 8785398 was granted and assigned to Bristol-Myers Squibb on July, 2014 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent

Patent attributes

Current Assignee

Bristol-Myers Squibb

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

87853980

Patent Inventor Names

Joseph Naemura0

Robert James Peach0

Peter S. Linsley0

Jurgen Bajorath0

Date of Patent

July 22, 2014

Patent Application Number

132774250

Date Filed

October 20, 2011

Patent Citations Received

‌

US Patent 11753458 CTLA-4 variant immunomodulatory proteins and uses thereof

Patent Primary Examiner

‌

Ilia Ouspenski

No article content yet.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 8785398 Methods of treatment using CTLA4 mutant molecules

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API